p53 Mutations, Methylation and Genomic Instability in the Progression of Chronic Myeloid Leukaemia

References

• Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767
   PubMed Web of Science ®Google Scholar
• Brown W. M. C., Doll R. Mortality from cancer and other causes after radiotherapy for alkylosing spondylitis. British Medical Journal 1965; 2: 1327–1332
   PubMed Web of Science ®Google Scholar
• Marshall C.J., Rigby P. W. J. Viral and cellular genes involved in oncogenesis. Cancer Surveys 1984; 3: 183–214
   Google Scholar
• Farrow A., Jacobs A., West R.R. Myelodysplasia, chemical exposure and other environmental factors. Leukemia 1989; 3: 33–35
   PubMed Web of Science ®Google Scholar
• Yuasa Y., Srivastava S.K., Dunn C.Y., Rhim J.S., Reddy E.P., Aaronson S.A. Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature 1983; 303: 775–779
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., Croce C.M. Human c-myc one gene is located on the region of chroinosoine 8 that is translocated in Burkitt lymphoma cells. Proceedings of the National Academy of Science USA 1982; 79: 7824–7827
   PubMed Web of Science ®Google Scholar
• Sap J., Munoz A., Schmitt J., Stinneneberg H., Vennstrorn H. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature 1989; 340: 242–244
   PubMed Web of Science ®Google Scholar
• Lane D.P., Crawford L.V. T-antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261–263
   PubMed Web of Science ®Google Scholar
• DeCaprio J.A., Ludlow J.W., Figge J., Shew J.Y., Huang C.M., Lee W.H., Marsilio E., Paucha E., Livingston D.M. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54: 275–283
   PubMed Web of Science ®Google Scholar
• Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C., Vogelstein B. Mutations in the p53 gene occur in diverse tumour types. Nature 1989; 342: 705–708
   PubMed Web of Science ®Google Scholar
• Linzer D. I. H., Levine A.J. Characterization of a 54K dalton cellular SV40 tumour antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Call 1979; 17: 43–52
   Google Scholar
• DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., Old L.J. Detection of transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proceedings of the National Academy of Science USA 1979; 76: 2420–2424
   PubMed Web of Science ®Google Scholar
• Eceles D., Cranston G., Steel C.M., Nakamura Y., Leonard R. Allele losses on chromosome 17 in human epithelial ovarian cancer. Oncogene 1990; 5: 1599–1601
   PubMed Web of Science ®Google Scholar
• Mackay J., Steel C.M., Elder P.A., Forrest A.P., Evan H.J. Allele loss on the short arm of chromosome 17 in breaht cancers. Lancet 1988; 2: 1384–1385
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Fearon E.R., Kern S.E., Hamilton S.R., Preisinger A.C., Nakamura Y., White R. Allelotype or colorectal carcinomas. Science 1989; 244: 207–211
   PubMed Web of Science ®Google Scholar
• Isobe M., Emmanuel B.S., Givol D., Oren M., Croce C.M. Localisation of gene for human p53 tumour antigen to bank 17p13. Nature 1986; 320: 84–85
   PubMed Web of Science ®Google Scholar
• Sousai T., de Fromentel C.C., Mechali M., May P., Kress M. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene 1987; 1: 71–78
   PubMed Web of Science ®Google Scholar
• Krawezak M., Smith-Sorensen B., Schmidtke J., Kakkar W., Cooper D.N., Hovig E. Somatic spectrum of cancer-associated single basepeir substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Human Mutation 1995; 5: 48–57
   PubMed Web of Science ®Google Scholar
• Wada H., Asada M., Nakazawa S., Itoh H., Kobayashi Y., Inoue T., Fukumuro K., Chan L.C., Sugita K., Hanada R., Akula N., Kohayahi N., Mizutani S. Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 1994; 8: 53–59
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Taniwaki M., Horiike S., Takashima T., Seriu T., Nakagawa H., Fujii H., Shimazaki C., Maruo N., Akaogi T., Uike N., Ahe T., Kashima K. Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. British Journal of Haematology 1994; 87: 425–427
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Toguchida J., Yandell D.W., Ishiznki K. Frequent p53 gene mutations in blast crisis ol chronic rnyelogenous leukemia, especially in myeloid crisis harboring loss of chromosome 17p. Cancer Research 1992; 52: 6588–6593
   PubMed Web of Science ®Google Scholar
• Borgstrom G.H., Vuopio P., de la Chapelle A. Abnormalities of chromosome 17 in myeloproliferative disorders. Cancer Genetics & Cytogenetics 1982; 5: 123–135
   PubMed Web of Science ®Google Scholar
• Rodriguez M.A., Ford K.J., Goodacre A., Selvanayagam P., Cabanillas F., Deisseroth A.B. Chromosome 17p and p53 changes in lymphoma. British Journal of Haematology 1991; 79: 575–582
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Horiike S., Meekawa T., Kashima K., Ishizaki K. Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. British Journal of Haematology 1995; 90: 147–155
   PubMed Web of Science ®Google Scholar
• Knudson A.G. Mutation and cancer: Statistical study of retinoblastoma. Proceedings of the National Academy of Sciences USA 1971; 68: 820–823
   PubMed Web of Science ®Google Scholar
• Lane D.P. p53, guardian of the genome. Nature 1992; 358: 15–16
   PubMed Web of Science ®Google Scholar
• Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Research 1991; 51: 6304–6311
   PubMed Web of Science ®Google Scholar
• Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 786–787
   PubMed Web of Science ®Google Scholar
• Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.M. Wild type p53 restores cell cycle and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937–948
   PubMed Web of Science ®Google Scholar
• Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923–935
   PubMed Web of Science ®Google Scholar
• Hartwell L. Defects in a cell cycle checkpoint may he responsible for the genomic instability of cancer cells. Cell 1992; 71: 543–546
   PubMed Web of Science ®Google Scholar
• Carder P.J., Cripps K.J., Morris R., Collins S., White S., Bird C.C., Wyllie A.H. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. British Journal of Cancer 1995; 71: 215–218
   PubMed Web of Science ®Google Scholar
• Wada C., Shionoya S., Fujino Y., Tokuhiro T., Akahoshi T., Uchida T., Ohtani H. Genomic instability of rnicrosatellite repeats and its association with the evolution of chronic myelogenous leukemia. British 1994; 83: 3449–3456
   Google Scholar
• Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. American Journal of Medicine 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Silver R.T. Chronic myeloid leukemia. A perspective of the clinical and biological issues of the chronic phase. Haematology and Oncology Clinics of North American 1990; 4: 319–323
   PubMed Web of Science ®Google Scholar
• Rowley J.D., Testa J.R. Chromosomal abnormalilies in malignant haematalogic diseases. Advances in Cancer Research 1982; 36: 103–148
   PubMed Web of Science ®Google Scholar
• Nowell P.C., Hungerford D.A. Chromosome studies on normal and leukemic human leukocytes. Journal of the U.S. National Cancer Institute 1960; 25: 85–93
   PubMed Web of Science ®Google Scholar
• Caspersson T., Gahrton G., Lindsten J., Zech L. Identification of the Philadelphia chromosome as a number 22 by quinaerine mustard fluorescence analysis. Experimental Cell Research 1970; 63: 238–240
   PubMedGoogle Scholar
• Kowley J.D. Letter: A new consistent chromosome abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Pendergast A.M., Muller A.J., Havlik M.H., Maru Y., Witte O.N. BCK sequences essential for transformation by the BCK-ABL. oncogene bind to the ABL SH2 regulatory domain in a non-phoshotyrosine-dependent manner. Cell 1991; 66: 161–171
   PubMed Web of Science ®Google Scholar
• Muller A.J., Pendergast A.M., Havlik M.H., Puil L., Pawson T., Witte O.N. A limited set of SH2 domains binds BCK through a high affinity phosphotyrosine-independent interaction. Molucular & Cellular Biology 1992; 12: 5087–5093
   PubMed Web of Science ®Google Scholar
• Pawson T. Non-catalytic domains of cytoplasmic protein-tyrosine kinases: regulatory elements in signal transduction. Oncogene 1988; 3: 491–495
   PubMed Web of Science ®Google Scholar
• Diekmann D., Brill S., Garrett M.D., Totty N., Hsuan J., Monfries C., Hall C., Lim L., Hall A. Bcr encodes GTPase-activating protein for p21Rac. Nature 1991; 351: 400–402
   PubMed Web of Science ®Google Scholar
• Maru Y.M., Witte O.N. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 1991; 67: 459–468
   PubMed Web of Science ®Google Scholar
• Scott M.L., Van Etten K.A., Daley G.Q., Baltimore D. v-abl causes hemopoietic disease distinct from that caused by bcr-abl. Proceedings of the National Academy of Sciences USA 1991; 88: 6506–6510
   PubMed Web of Science ®Google Scholar
• Pendergast A.M., Muller A.J., Havlik M.H., Clark R., McCormick F., Witte O.N. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proceedings of the National Activity of Sciences USA 1991; 88: 5927–5931
   PubMed Web of Science ®Google Scholar
• Kaye F.J., Najfeld V., Singer J., Cuttner J., Fialkow P.J. Confirming evidence for the clonal development and stem cell origin of Philadelphia chromosome-negative chronic myelogenous leukemia. American Journal of Hematology 1984; 17: 93–96
   PubMed Web of Science ®Google Scholar
• Lisker F., Casas L., Mutchinick O., Perez-Chavez F., Labardini J. Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood 1980; 56: 812–814
   PubMed Web of Science ®Google Scholar
• Frassoni F., Repetto M., Podesta M., Piaggo G., Raffo M.R., Sessarego M., Bacigalupo A., Marmont A.M. Competitive survival/prolifelation of normal and Ph1 -positive haemopoietic cells. British Journal of Haematology 1986; 63: 135–141
   PubMed Web of Science ®Google Scholar
• Sokal J.E., Gomez G.A., Baccarani M., Tura S., Clarkson B.D., Cervantes F., Rozman C., Carbonell F., Anger B., Heimpel H., Nissen N. 1., Robertson J.E. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294–298
   PubMed Web of Science ®Google Scholar
• Mitelman F. The cytogenetic scenario of chronic rnyeloid leukaemia. Leukemia and Lymphoma 1993; 11: 11–15
   PubMed Web of Science ®Google Scholar
• Sawyers C.L. The role of myc in transformation by BCR-ABL. Leukemia and Lymphoma 1993; 11: 45–46
   PubMed Web of Science ®Google Scholar
• Mori N., Wada M., Yokota J., Terada M., Okada M., Teramura M., Masuda M., Hoshino S., Motoji T., Oshimi K., Mizuguchi H. Mutations of the p53 tumour suppressor gene in haematological neoplasms. British Journal of Haematology 1992; 81: 235–240
   PubMed Web of Science ®Google Scholar
• Fenaux P., Preudhomme C., Quiquandon I., Jonveux P., Lai J.L., Vanrumbeke M., Loucheux-Lefebvre M.H., Bauters F., Berger K., Kerckaert J.P. Mutations of the p53 gene in acute myeloid leukaemia. British Journal of Haematology 1992; 80: 178–183
   PubMed Web of Science ®Google Scholar
• Jonveux P., Fenaux P., Quiquandon I., Pignon J.M., Lai J.L., Loucheux-Lefebvre M.H., Goossens M., Bauters F., Berger K. Mutations in the p53 gene in myelodys-plastic syndromes. Oncogene 1991; 6: 2243–2247
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Advani S.H., Benchimol S., Cline M.J. Alterations in the p. 53 gene and the clonal evolution of the blast crisis in chronic myelocytic leukemia. Proceedings of the National Academy of Sciences USA 1989; 86: 6783–6787
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Arlin Z., Advani S., Allen S.L., Goldman J., Snyder D., Foti A., Cline M. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. Journal of Clinical Investigation 1991; 87: 2042–2047
   PubMed Web of Science ®Google Scholar
• Mashal K., Shtalrid M., Talpaz M., Kantarjian H., Smith L., Beran M., Cork A., Trujillo J., Gutterman J., Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Foti A., Ahuja H.G., Allen S.L., Koduru P., Schuster M.W., Schulman P., Bar-Eli M., Cline M.J. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia in blast crisis. Blood 1991; 77: 2441–2444
   PubMed Web of Science ®Google Scholar
• Guinn B.A., Smith M., Padua K.A., Burnett A.K., Mills K.I. Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research 1995; 19: 519–525
   PubMed Web of Science ®Google Scholar
• Feinstein E., Cimino C., Gale K.P., Alimena G., Berthier K., Kishi K., Goldinan J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proceedings of the National Academy of Science, USA 1991; 88: 6293–6297
   PubMed Web of Science ®Google Scholar
• Foti A., Cline M.J. Sequential relapses of blastic crisis may involve different clones of cells with different molecular abnormalities. British Journal of Haematology 1994; 87: 627–630
   PubMed Web of Science ®Google Scholar
• Kurosawa M., Okabe M., Kunieda Y., Miyazaki T. p53 mutation in the chronic phase was not detected in the myeloid crisis of a chronic myelocytic leukemia case. Blood 1994; 83: 2750–2152
   PubMed Web of Science ®Google Scholar
• Laneuville P., Sun G., Timm M., Vekemans M. Clonal evolution in a myeloid cell line transformed to inter-leukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80: 1788–1797
   PubMed Web of Science ®Google Scholar
• Lin S.Y., Kiggs A.D. Lac operator analogues: bromodeoxyuridine substitution in the lac operator affects the rate of dissociation of the lac repressor. Proceedings of the National Academy Sciecce USA 1972; 69: 2574–2576
   PubMed Web of Science ®Google Scholar
• Fischer E.F., Caruthers M.H. Studies on gene control regions XII. The functional significance of a Lac operator constitutive mutation. Nucleic Acids Research 1979; 7: 401–416
   PubMed Web of Science ®Google Scholar
• Smith H.O. Nucleotide sequence specificity of restriction endonucleases. Science 1979; 205: 455–462
   PubMed Web of Science ®Google Scholar
• Pollack Y., Stein K., Razin H., Cedar H. Methylation of foreign DNA sequences in eukaryotic cells. Proceodings of the National Academy Science USA 1980; 77: 6463–6467
   PubMed Web of Science ®Google Scholar
• Vovis G.F., Horiuchi K., Zinder N.D. Kinetics of methylation of DNA by restriction endonuclease from Escherichia coli B. Proceedings of the National Academy Science USA 1974; 71: 3810–3813
   PubMed Web of Science ®Google Scholar
• Bird A.P. Use of restriction enzymes to study eukaryotic DNA methylation: II. The symmetry of methylated sites supports semi-conservative copying of the methylation pattern. Journal of Molecular Biology 1978; 118: 49–60
   PubMed Web of Science ®Google Scholar
• Bird A.P. CpG-rich islands and the function of DNA methylation. Nature (London) 1986; 321: 209–213
   PubMed Web of Science ®Google Scholar
• Hillyard C.J., Oscier D.G., Foa R., Catovsky D., Coldman J.M. Immunoreactive calcitonin in leukaemia. British Medical Journal 1979; 2: 1392–1393
   PubMed Web of Science ®Google Scholar
• Foa R., Oscier D.G., Hillyard C.J., Incarbone E., MacIntyre I., Goldman J.M. Production of immunoreactive calcitonin by myeloid leukaemia cells. British Journal of Haematology 1982; 50: 215–223
   PubMed Web of Science ®Google Scholar
• Koeppler H., Pfleuger K.H., Knapp W., Havemann K. Establishment of three permanent human leukaemia cell lines producing immunoreactive calcitonin. British Journal of Haematology 1987; 65: 405–409
   PubMed Web of Science ®Google Scholar
• Foa P., Ortolani S., Pogliani E.M., Lurlo A., Gualdoni A., Maiolo A.T., Polli E.E. Immunoreactive calcitonin: a tumor marker for myelogenous leukemias. Internatational Journal of Biological Markers 1990; 5: 27–30
   PubMedGoogle Scholar
• Riggs A.D., Jones P.A. S-Methylcytosine, gene regulation and cancer. Advances in Cancer Research 1983; 40: 1–30
   PubMed Web of Science ®Google Scholar
• Feinberg A.P., Vogelstein 9. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89–92
   PubMed Web of Science ®Google Scholar
• Baylin S.B., Hoppener J. W. M., de Bustros A., Steenbergh P.H., Lips C. J. M., Nelkin B.D. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Research 1986; 46: 2917–2922
   PubMed Web of Science ®Google Scholar
• Baylin S.B., Fearon E.R., Vogelstein B., de Bustros A., Sharkis S.J., Burke P.J., Staal S.P., Nelkin B.D. Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 1987; 70: 412–417
   PubMed Web of Science ®Google Scholar
• Malinen T., Palotie A., Pakkala S., Peltonen L., Ruutu T., Jansson S.-E. Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 1991; 77: 2435–2440
   PubMed Web of Science ®Google Scholar
• Mills K.I., Guinn B.A., Walsh V., Burnett A.K. Calcitonin methylation, p53 mutations and disease progression in CML. Leukemia Research 1996; 20: 771–775
   PubMed Web of Science ®Google Scholar
• Ohyashiki J.H., Ohyashiki K., Kawakubo T., Tauchi T., Shimamoto T., Toyama K. The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells. Leukemia 1993; 7: 801–807
   PubMed Web of Science ®Google Scholar
• Litz C.E., Goldfarb A.N., Strickler J.G., Brunning R.D. Presence of lineage-specific hypomethylated sites in the major breakpoint cluster region. Cancer Research 1990; 50: 4984–4990
   PubMed Web of Science ®Google Scholar
• Litz C.E., McClure J.S., Coad J.E., Goldfarb A.N., Brunning R.D. Methylation status of the major breakpoint cluster region in Philadelphia chromosome negative leukemias. Leukemia 1992; 6: 35–31
   PubMed Web of Science ®Google Scholar
• Mills K.I., Sproul A.M., Burnett A.K. Methylation of the major breakpoint cluster region (M-BCR) in Philadelphia-positive CML. Leukemia 1993; 7: 707–711
   PubMed Web of Science ®Google Scholar
• Ohtsuki T., Nishitani K., Hatamochi A., Yawata Y., Namba M. Analysis of methylation in the c-MYC gene in five human myeloma cell lines. British Journal of Haematology 1991; 77: 172–179
   PubMed Web of Science ®Google Scholar
• Hoffman R.M. Unbalanced transmethylation and the perturbation of the differentiated state leading to cancer. Bioessays 1990; 12: 163–166
   PubMed Web of Science ®Google Scholar
• Lewis J., Bird A. DNA methylation and chromatin structure. FEBS Letters 1991; 285: 155–159
   PubMed Web of Science ®Google Scholar
• Smith S.S. DNA methylation in eukaryotic chromosome satability. Molecular Carcinogenesis 1991; 4: 91–92
   PubMed Web of Science ®Google Scholar
• Pogribny I.P., Basnakian A.G., Miller B.J., Lopatina N.G., Poirier L.A., James S.J. Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Research 1995; 55: 1894–1901
   PubMed Web of Science ®Google Scholar
• Cariello N.F., Cui L., Beroud C., Soussi T. Database and software for the analysis of mutations in the human p53 gene. Cancer Research 1994; 54: 4454–4460
   PubMed Web of Science ®Google Scholar
• Zion M., Ben-Yehuda D., Avraham A., Cohen O., Wetyler M., Melloul D., Ben-Neriah Y. Progressive de novo DNA methylation at the BCR-ABL locus in the course of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences. USA 1994; 91: 10722–10726
   PubMed Web of Science ®Google Scholar
• Nelkin B.D., Przepiorka D., Burke P.J., Thomas E.D., Baylin S.B. Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood 1991; 77: 2431–2434
   PubMed Web of Science ®Google Scholar